arXiv subjects

Akeem Temitope Otapo

Publications and source records attributed to Akeem Temitope Otapo.

2 recordsLinked to original sources

arXiv2026

Leakage-Controlled Multimodal Learning for Diagnosis and Progression Prediction in Alzheimer's Disease Research

Alzheimer's disease prediction involves irregular visits, heterogeneous measurements and incomplete modalities. This study presents a multimodal multitask framework combining an adapted SFCN MRI encoder, four causal clinical Transformers, shared fusion and task-specific ODE-GRU dynamics. Fine-tuning and LoRA adapt the final two MRI blocks. Task-DRO balances task losses, while Group-CVaR targets cohort and comorbidity strata. Branch-specific input controls, subject-grouped partitions and empirical causality checks support longitudinal evaluation. Across 2,649 subjects and 17,317 visits from ADNI, OASIS-2 and MIRIAD, internal validation yields diagnosis, stage-1 progression and first-stage-1-visit progression AUROCs of 0.935 +/- 0.002, 0.884 +/- 0.003 and 0.870 +/- 0.005, respectively (mean +/- SD across three seeds). Corresponding hybrid AUROCs are 0.951, 0.909 and 0.896. Next-visit MMSE mean absolute error (MAE) is 1.61 points; worst-stratum diagnosis AUROC is 0.827 +/- 0.008. Sampled ADNI explanations identify task-specific input dependence. OASIS-3 external validation yields network and hybrid diagnosis AUROCs of 0.763 and 0.767, hybrid next-visit progression AUROC of 0.764, diagnosis calibration error decreasing from 0.197 to 0.052, and next-visit MMSE MAE of 0.86. Seed-42 paired ablations of six components yield pooled diagnosis and progression AUROC differences between -0.004 and +0.004; removing clinical encoder inputs lowers diagnosis AUROC by 0.272. The framework integrates longitudinal prediction, missing-modality handling, auxiliary comorbidity modelling and subgroup evaluation within a common pipeline.

cs.LG↗

arXiv2024

Prediction and Detection of Terminal Diseases Using Internet of Medical Things: A Review

The integration of Artificial Intelligence (AI) and the Internet of Medical Things (IoMT) in healthcare, through Machine Learning (ML) and Deep Learning (DL) techniques, has advanced the prediction and diagnosis of chronic diseases. AI-driven models such as XGBoost, Random Forest, CNNs, and LSTM RNNs have achieved over 98\% accuracy in predicting heart disease, chronic kidney disease (CKD), Alzheimer's disease, and lung cancer, using datasets from platforms like Kaggle, UCI, private institutions, and real-time IoMT sources. However, challenges persist due to variations in data quality, patient demographics, and formats from different hospitals and research sources. The incorporation of IoMT data, which is vast and heterogeneous, adds complexities in ensuring interoperability and security to protect patient privacy. AI models often struggle with overfitting, performing well in controlled environments but less effectively in real-world clinical settings. Moreover, multi-morbidity scenarios especially for rare diseases like dementia, stroke, and cancers remain insufficiently addressed. Future research should focus on data standardization and advanced preprocessing techniques to improve data quality and interoperability. Transfer learning and ensemble methods are crucial for improving model generalizability across clinical settings. Additionally, the exploration of disease interactions and the development of predictive models for chronic illness intersections is needed. Creating standardized frameworks and open-source tools for integrating federated learning, blockchain, and differential privacy into IoMT systems will also ensure robust data privacy and security.

cs.LG↗